Literature DB >> 19028508

Impaired NHEJ function in multiple myeloma.

Clara Yang1, Christopher Betti, Sheetal Singh, Amir Toor, Andrew Vaughan.   

Abstract

Multiple myeloma (MM) is characterized by multiple chromosomal aberrations. To assess the contribution of DNA repair to this phenotype, ionizing radiation was used to induce DNA double strand breaks in three MM cell lines. Clonogenic survival assays showed U266 (SF4=15.3+6.4%) and RPMI 8226 (SF4=12.6.0+1.7%) were radiation sensitive while OPM2 was resistant (SF4=78.9+4.1%). Addition of the DNA-PK inhibitor NU7026 showed the expected suppression in radiation survival in OPM2 but increased survival in both radiation sensitive cell lines. To examine non-homologous end joining (NHEJ) repair in these lines, the ability of protein extracts to support in vitro DNA repair was measured. Among the three MM cell lines analyzed, RPMI 8226 demonstrated impaired blunt ended DNA ligation using a ligation-mediated PCR technique. In a bacterial based functional assay to rejoin a DNA break within the beta-galactosidase gene, RPMI 8226 demonstrated a 4-fold reduction in rejoining fidelity compared to U266, with OPM2 showing an intermediate capacity. Ionizing radiation induced a robust gamma-H2AX response in OPM2 but only a modest increase in each radiation sensitive cell line perhaps related to the high level of gamma-H2AX in freshly plated cells. Examination of gamma-H2AX foci in RPMI 8226 cells confirmed data from Western blots where a significant number of foci were present in freshly plated untreated cells which diminished over 24h of culture. Based on the clonogenic survival and functional repair assays, all three cell lines exhibited corrupt NHEJ repair. We conclude that suppression of aberrant NHEJ function using the DNA-PK inhibitor NU7026 may facilitate access of DNA ends to an intact homologous recombination repair pathway, paradoxically increasing survival after irradiation. These data provide insight into the deregulation of DNA repair at the site of DNA breaks in MM that may underpin the characteristic genomic instability of this disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19028508      PMCID: PMC2875794          DOI: 10.1016/j.mrfmmm.2008.10.019

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  44 in total

1.  Hypodiploidy is a major prognostic factor in multiple myeloma.

Authors:  N V Smadja; C Bastard; C Brigaudeau; D Leroux; C Fruchart
Journal:  Blood       Date:  2001-10-01       Impact factor: 22.113

2.  Increased error-prone NHEJ activity in myeloid leukemias is associated with DNA damage at sites that recruit key nonhomologous end-joining proteins.

Authors:  Nicola Brady; Terry J Gaymes; Manyee Cheung; Ghulam J Mufti; Feyruz V Rassool
Journal:  Cancer Res       Date:  2003-04-15       Impact factor: 12.701

3.  Human chronic lymphocytic leukemia B cells can escape DNA damage-induced apoptosis through the nonhomologous end-joining DNA repair pathway.

Authors:  Ludovic Deriano; Olivier Guipaud; Hélène Merle-Béral; Jacques-Louis Binet; Michelle Ricoul; Gaby Potocki-Veronese; Vincent Favaudon; Zofia Maciorowski; Catherine Muller; Bernard Salles; Laure Sabatier; Jozo Delic
Journal:  Blood       Date:  2005-02-17       Impact factor: 22.113

Review 4.  Role of RAD52 epistasis group genes in homologous recombination and double-strand break repair.

Authors:  Lorraine S Symington
Journal:  Microbiol Mol Biol Rev       Date:  2002-12       Impact factor: 11.056

5.  Ku86 variant expression and function in multiple myeloma cells is associated with increased sensitivity to DNA damage.

Authors:  Y T Tai; G Teoh; B Lin; F E Davies; D Chauhan; S P Treon; N Raje; T Hideshima; Y Shima; K Podar; K C Anderson
Journal:  J Immunol       Date:  2000-12-01       Impact factor: 5.422

6.  Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.

Authors:  S Rajkumar; R Fonseca; M Lacy; T Witzig; J Lust; P Greipp; T Therneau; R Kyle; M Litzow; M Gertz
Journal:  Bone Marrow Transplant       Date:  1999-09       Impact factor: 5.483

7.  A mutation in mouse rad51 results in an early embryonic lethal that is suppressed by a mutation in p53.

Authors:  D S Lim; P Hasty
Journal:  Mol Cell Biol       Date:  1996-12       Impact factor: 4.272

8.  Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: primary breakpoints and clinical correlations.

Authors:  M J Calasanz; J C Cigudosa; M D Odero; C Ferreira; M T Ardanaz; A Fraile; J L Carrasco; F Solé; B Cuesta; A Gullón
Journal:  Genes Chromosomes Cancer       Date:  1997-02       Impact factor: 5.006

9.  DNA end-joining catalyzed by human cell-free extracts.

Authors:  P Baumann; S C West
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

10.  Effects of radiation fractionation on four squamous cell carcinoma lines with dissimilar inherent radiation sensitivity.

Authors:  K Pekkola-Heino; J Kulmala; P Klemi; T Lakkala; K Aitasalo; H Joensuu; R Grenman
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

View more
  21 in total

1.  Suberoylanilide hydroxyamic acid modification of chromatin architecture affects DNA break formation and repair.

Authors:  Sheetal Singh; Hongan Le; Shyh-Jen Shih; Bay Ho; Andrew T Vaughan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-02-01       Impact factor: 7.038

2.  A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition.

Authors:  David A Alagpulinsa; Srinivas Ayyadevara; Shmuel Yaccoby; Robert J Shmookler Reis
Journal:  Mol Cancer Ther       Date:  2015-12-30       Impact factor: 6.261

Review 3.  DNA repair pathways in human multiple myeloma: role in oncogenesis and potential targets for treatment.

Authors:  Claire Gourzones-Dmitriev; Alboukadel Kassambara; Surinder Sahota; Thierry Rème; Jérôme Moreaux; Pascal Bourquard; Dirk Hose; Philippe Pasero; Angelos Constantinou; Bernard Klein
Journal:  Cell Cycle       Date:  2013-08-09       Impact factor: 4.534

4.  A peptide nucleic acid targeting nuclear RAD51 sensitizes multiple myeloma cells to melphalan treatment.

Authors:  David Abasiwani Alagpulinsa; Shmuel Yaccoby; Srinivas Ayyadevara; Robert Joseph Shmookler Reis
Journal:  Cancer Biol Ther       Date:  2015-05-21       Impact factor: 4.742

5.  Evidence for ongoing DNA damage in multiple myeloma cells as revealed by constitutive phosphorylation of H2AX.

Authors:  D K Walters; X Wu; R C Tschumper; B K Arendt; P M Huddleston; K J Henderson; A Dispenzieri; D F Jelinek
Journal:  Leukemia       Date:  2011-05-13       Impact factor: 11.528

6.  Effects of the novel DNA dependent protein kinase inhibitor, IC486241, on the DNA damage response to doxorubicin and cisplatin in breast cancer cells.

Authors:  David Davidson; Jeremy Grenier; Veronica Martinez-Marignac; Lilian Amrein; May Shawi; Marc Tokars; Raquel Aloyz; Lawrence Panasci
Journal:  Invest New Drugs       Date:  2011-05-13       Impact factor: 3.850

7.  Effects of dna-dependent protein kinase inhibition by NU7026 on dna repair and cell survival in irradiated gastric cancer cell line N87.

Authors:  M T Niazi; G Mok; M Heravi; L Lee; T Vuong; R Aloyz; L Panasci; T Muanza
Journal:  Curr Oncol       Date:  2014-04       Impact factor: 3.677

8.  Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors.

Authors:  Paola Neri; Li Ren; Kathy Gratton; Erin Stebner; Jordan Johnson; Alexander Klimowicz; Peter Duggan; Pierfrancesco Tassone; Adnan Mansoor; Douglas A Stewart; Sagar Lonial; Lawrence H Boise; Nizar J Bahlis
Journal:  Blood       Date:  2011-09-13       Impact factor: 22.113

9.  Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells.

Authors:  David Davidson; Yannick Coulombe; Veronica L Martinez-Marignac; Lilian Amrein; Jeremy Grenier; Keira Hodkinson; Jean-Yves Masson; Raquel Aloyz; Lawrence Panasci
Journal:  Invest New Drugs       Date:  2011-01-11       Impact factor: 3.850

10.  Dendritic cell-mediated activation-induced cytidine deaminase (AID)-dependent induction of genomic instability in human myeloma.

Authors:  Srinivas Koduru; Ellice Wong; Till Strowig; Ranjini Sundaram; Lin Zhang; Matthew P Strout; Richard A Flavell; David G Schatz; Kavita M Dhodapkar; Madhav V Dhodapkar
Journal:  Blood       Date:  2012-01-10       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.